The U.S. Department of Health and Human Services announced a sweeping effort on Monday aimed at strengthening America’s role in clinical research, accelerating the development of new treatments, and encouraging more medical studies to take place in the United States.
The initiative brings together multiple HHS agencies in what officials described as a coordinated strategy to reduce barriers to clinical trials and expand access to innovative therapies.
According to HHS, the effort is designed to address concerns that an increasing share of early-stage clinical research has moved overseas in recent years, potentially weakening the nation’s position as a leader in biomedical innovation.
Kennedy Says U.S. Must Reclaim Research Leadership
HHS Secretary Robert F. Kennedy Jr. said the department is working to make the United States a more attractive location for clinical research and drug development.
“America should be the best place in the world to develop new medicines, yet we have built a system that drives too much clinical research overseas,” Kennedy said in a statement.
“Under President Trump’s leadership, HHS is launching a coordinated department-wide effort to restore America’s leadership in clinical research, remove unnecessary barriers, and bring more clinical research and investment back to the United States. America led the world in medical innovation before. We will lead again.”
FDA Proposes Changes To Speed Drug Development
As part of the initiative, the Food and Drug Administration is seeking public input on a pilot program aimed at shortening the timeline between drug discovery and first-in-human Phase 1 clinical trials.
The agency also said it is clarifying regulatory expectations that could reduce early trial timelines by six to 12 months.
In addition, the FDA has issued draft guidance stating that, in many cases, a single high-quality late-stage clinical trial supported by confirmatory evidence may be sufficient to demonstrate a drug’s effectiveness for approval.
NIH Expands Focus On New Research Tools
The National Institutes of Health said it will continue supporting large, well-designed clinical trials while expanding the use of emerging technologies and research methods.
The agency plans to advance responsible use of artificial intelligence, human cell-based models, real-world data, and practical clinical trial tools intended to help move promising therapies to patients more efficiently.
HHS also highlighted efforts by NIH’s National Center for Advancing Translational Sciences to build on work that led to the first fully personalized CRISPR-based gene-editing treatment and accelerate future therapies for patients with rare diseases.
Meanwhile, the NIH’s National Cancer Institute is working with researchers and cancer centers to streamline trial activation and improve enrollment in cancer studies.
Technology And AI Included In Modernization Effort
The Office of the National Coordinator for Health Information Technology is exploring ways to connect patients with clinical trials through electronic health records, allowing eligible patients to learn about research opportunities during routine medical care.
HHS also pointed to new initiatives from the Advanced Research Projects Agency for Health, known as ARPA-H.
Programs such as THRIVE and CATALYST are designed to modernize clinical research by leveraging artificial intelligence and machine learning to predict treatment safety, optimize dosing, and improve trial efficiency before patients are enrolled.
Review Of Federal Regulations Planned
The HHS Office of Inspector General is seeking public feedback on whether changes are needed to certain federal regulations related to clinical trial participation.
The review will examine possible updates to safe harbor regulations under the federal anti-kickback statute and rules governing incentives provided to clinical trial participants.
Goal Is Faster Access To New Treatments
HHS said the combined effort aims to reduce delays in clinical research, increase participation in studies, strengthen domestic research capacity, and ensure future medical breakthroughs are developed in the United States.
Department officials said success will require collaboration among government agencies, pharmaceutical companies, academic medical centers, contract research organizations, healthcare providers, and patient advocacy groups.
The department said it will continue working with stakeholders to identify obstacles that slow research and remove unnecessary barriers to innovation.
According to HHS, the initiative reflects a broader effort to strengthen American scientific leadership, expand access to cutting-edge treatments, and maintain the nation’s position as a global leader in medical innovation.
